Doctors try existing CF drugs on patients left behind by current treatments
NCT ID NCT03587961
Summary
This early study is testing whether three existing cystic fibrosis drugs (Symdeko, Orkambi, and Kalydeco) might help patients who have rare genetic mutations that aren't currently approved for these treatments. Researchers will give 20 participants the drug that lab tests suggest might work best for their specific mutation. The main goal is to see if these 'off-label' uses can improve lung function in people with these uncommon CF mutations.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35233, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.